Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) will likely be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of ($0.1317) per share for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, analysts expect Trevi Therapeutics to post ($0.48) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.
Trevi Therapeutics Stock Performance
TRVI stock opened at $14.33 on Friday. The stock’s 50 day simple moving average is $14.27 and its 200 day simple moving average is $14.39. Trevi Therapeutics has a fifty-two week low of $9.82 and a fifty-two week high of $20.22. The company has a market cap of $2.04 billion, a P/E ratio of -42.15 and a beta of 1.15.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Trevi Therapeutics
Insider Transactions at Trevi Therapeutics
In other Trevi Therapeutics news, Director Michael Heffernan sold 39,473 shares of Trevi Therapeutics stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total transaction of $595,647.57. Following the completion of the transaction, the director owned 6,351 shares in the company, valued at approximately $95,836.59. The trade was a 86.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 15.39% of the company’s stock.
About Trevi Therapeutics
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.
Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder.
Further Reading
- Five stocks we like better than Trevi Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
